Clinical Trial Update: CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CAELYX® as adjuvant treatment in early-stage Luminal B breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)

Snippet

Sponsor: European Institute of Oncology | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN